Skip to content

Clinical Study in Post-operation Treatment of Cervical Cancer

Status and the Application of Topotecan at Post-operation Treatment of Cervical Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01418859
Enrollment
183
Registered
2011-08-17
Start date
2011-08-31
Completion date
2015-12-31
Last updated
2012-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

cervical cancer, postoperation, chemotherapy, radiotherapy

Brief summary

The purpose of the research is to evaluate the effect of additional chemotherapy in postoperation therapy of cervical cancer patients with risk factors (big tumor, deep invasion or tumor thrombi in the vascular system).

Detailed description

Cervical cancer has a very high morbidity. Many patients need additional therapy after surgery in order to elevate the survival rate and life quality. In this research, we are going to give additional therapy to patients who have big tumor, deep invasion or tumor thrombi in the vascular system after surgery. randomized control method will be used in this research, in order to compare the survival rate and side effects between radiation therapy only, concurrent chemoradiotherapy, and concurrent chemoradiotherapy with additional chemotherapy. 3D-CRT and Topotecan will be used in this research.

Interventions

None listed

Sponsors

Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. patients who underwent the cervical cancer radical surgery in three months have higt risk factors which including deep stromal invasion,large primary tumour and/or lymphovascular spase invasion; 2. squamous carcinoma; 3. age\<70; 4. Gynecologic Oncology Group (GOG):0-2.

Exclusion criteria

1. negative nodes,surgical margin,and/or parametrium; 2. No serious damage to the liver and kidney function, no hypertension,diabetes and other effects of therapy complications.

Countries

China

Contacts

Primary ContactLiu Zi, M.D
liuzmail@163.com86-18991232167
Backup ContactWang Tao, M.D
taowangmd@163.com86-18991232386

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026